Lexaria Corp (OTCMKTS:LXRP) is as Wobbly as Ever
Lexaria Corp (OTCMKTS:LXRP) issued a press release on Monday and thus, it guaranteed itself an interesting start of the week. Investors (who, by the looks of things, had forgotten about the stock) traded around 550 thousand shares, or about four and a half times the 30-day average, and their pushed the ticker to a close of over $0.20 for the first time in more than two months.
Sadly, staying above this psychological barrier is proving to be a tall order. Yesterday, after an even more impressive volume of 600 thousand shares, LXRP dropped by about 11% and it closed the session with a price of $0.19 per share.
Clearly, investors aren’t so sure about LXRP. Let’s find out why.
The truth is, LXRP is just one of the many OTC companies that rode the wave of excitement last year and changed their business focus from the oil and gas industry to the medical cannabis business. We probably don’t need to tell you that most of these companies failed to make any sort of impact on the marijuana industry and they are now approached with caution by OTC investors.
Unlike the majority of its pot stock counterparts, LXRP actually managed to release some products and generate some revenues, but even so, the management team tend to do things in an interesting way sometimes. On August 12, for example, they announced the launch of some new ViPova products, but it wasn’t until Monday, a full two weeks later, that they told us that the products in question actually work.
The press release that sparked the sudden increase in volume talked about some laboratory tests that the ViPova teas have gone through. The results show that thanks to LXRP‘s technology, the CBD absorption rate is 499% greater than the baseline products.
While the news sounds good, it’s still way too early to say whether LXRP can really turn the ViPova CBD products into a household name. A point hammered home by the 10-Q for the period ended May 31:
- cash: $832,101
- current assets: $1,157,896
- current liabilities: $62,604
- quarterly revenues: $7,187
- quarterly net loss: $511,008
Indeed, the company is still in the process of launching its products and drawing conclusions from the first months of sales probably won’t be that fair. Then again, there can be no guarantees that the revenue figures will ever be greater than the ones you see above.
To top it all off, there seems to be some promotional activity around LXRP. Yesterday, for example, about twenty-four hours after the company released the aforementioned test results, an entity called Emerging Growth LLC republished the positive news and said that Lexaria could be a game changer in the cannabis industry. According to the disclaimer, over the last twelve months, Emerging Growth has received a total of $53 thousand from LXRP for investor awareness services.
We’re not sure if the stock needs the additional promotion. Especially in light of the volatility it’s demonstrating.
